Results 1 to 10 of about 23,499 (227)
Materials and Design, 2023 FK506 has been widely used to prevent acute rejection in heart transplantation (HT). However, its strong hydrophobicity, poor bioavailability, high pharmacokinetic variability, and narrow therapeutic window are obstacles to its application in HT.
Chenyuan Wang, Qiaofeng Jin
exaly +3 more sources
Renal Failure, 1999 Tacolimus (FK506) is a potent immunosuppressive agent with significant nephrotoxic properties. FK506 is complexed with an intracellular binding protein FKBP-12. Both the immunosuppressive and nephrotoxic effects may be linked to the inhibitory effect of this complex on calcineurin.
William F Finn
exaly +3 more sources
HEPATOTROPHIC EFFECTS OF FK506 IN DOGS [PDF]
Transplantation, 1991 Portacaval shunt (Eck fistula) in dogs causes hepatocyte atrophy and organelle disruption, as well as tripling of hepatocyte mitoses. After submitting dogs to this procedure, FK506 was infused into the tied-off left portal vein. The size, anatomic quality, and replication of hepatocytes were enhanced in the portion of liver infused with FK506, with a ...
T. E. Starzl +5 more
openaire +5 more sources
FK506 causes pain by upregulating Na1.7 channels in the spinal dorsal root ganglia of Na1.7–ChR2 mice [PDF]
Molecular PainCalcineurin inhibitors, including tacrolimus (FK506), are used as immunosuppressive agents and can cause unexplained calcineurin inhibitor-induced pain syndrome (CIPS).
Toyoaki Maruta +4 more
doaj +2 more sources
Regulatory orchestration of FK506 biosynthesis in Streptomyces tsukubaensis NRRL 18488 revealed through systematic analysis [PDF]
iScienceSummary: Streptomyces tsukubaensis NRRL 18488, the primary producer of the immunosuppressant FK506, was analyzed to elucidate regulatory features of secondary metabolism.
Namil Lee +13 more
doaj +2 more sources
Healing of sub-critical femoral osteotomies in mice is unaffected by tacrolimus and deletion of recombination activating gene 1 [PDF]
European Cells & Materials, 2021 Clinical management of delayed healing or non-union of long bone fractures and segmental defects poses a substantial orthopaedic challenge. There are suggestions in the literature that bone healing may be enhanced by inhibiting the activities of T and B ...
T-Y Liu +9 more
doaj +1 more source
Optimization of the precursor supply for an enhanced FK506 production in Streptomyces tsukubaensis
Frontiers in Bioengineering and Biotechnology, 2022 Tacrolimus (FK506) is a macrolide widely used as immunosuppressant to prevent transplant rejection. Synthetic production of FK506 is not efficient and costly, whereas the biosynthesis of FK506 is complex and the level produced by the wild type strain ...
Susann Schulz +12 more
doaj +1 more source
PLoS ONE, 2023 The objective of this study was to determine if locally delivered FK506 could prevent allogeneic nerve graft rejection long enough to allow axon regeneration to pass through the nerve graft.
Brett Davis +8 more
doaj +1 more source
International Journal of Immunopathology and Pharmacology, 2021 To determine the effects of Tacrolimus (FK506) on Treg cells and subpopulations in SSc patients and assess the ability of FK506 to modify the immune imbalance of Treg/Th17 cells.
Xinjuan Liu +5 more
doaj +1 more source
Targeted Metabolomics Analysis Suggests That Tacrolimus Alters Protection against Oxidative Stress
Antioxidants, 2023 Tacrolimus (FK506) is an immunosuppressant that is experiencing a continuous rise in usage worldwide. The related side effects are known to be globally dose-dependent.
Marie Joncquel +14 more
doaj +1 more source